A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors.

被引：0
|
作者：
Schmid, P
Kiewe, P
Kuehnhardt, D
Korfel, A
Lindemann, S
Giurescu, M
Reif, S
Thiel, E
Possinger, K
机构：
[1] Humboldt Univ, Berlin, Germany
[2] Schering AG, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：147S / 147S
页数：1
相关论文
共 50 条
  • [1] Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors
    Schmid, P.
    Kiewe, P.
    Possinger, K.
    Korfel, A.
    Lindemann, S.
    Giurescu, M.
    Reif, S.
    Wiesinger, H.
    Thiel, E.
    Kuehnhardt, D.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 633 - 639
  • [2] Weekly administration of ZK-EPO, a novel third-generation epothilone, in patients with refractory solid tumors: Results of a phase I trial
    Arnold, Dirk
    Voigt, Wieland
    Kiewe, Philipp
    Behrmann, Curd
    Lindemann, Stefanie
    Reif, Stefanie
    Giurescu, Marius
    Thiel, Eckhard
    Schmoll, Hans-Joachim
    ANNALS OF ONCOLOGY, 2006, 17 : 138 - 138
  • [3] A phase I clinical pharmacokinetic study of sagopilone (ZK-EPO), a novel first fully synthetic epothilone, in Japanese patients with refractory solid tumors
    Minami, Hironobu
    Araki, Kazuhiro
    Kitagawa, Koichi
    Mukai, Hirofumi
    Mukohara, Toru
    Kodama, Keiji
    Ando, Yuichi
    Narabayashi, Masaru
    Sasaki, Yasutsuna
    Mera, Kiyomi
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [4] Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma
    Wenk, D.
    DeConti, R. C.
    Urbas, P.
    Andrews, S.
    Sondak, V. K.
    Maker, N.
    Weber, J. S.
    Daud, A. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer
    Rustin, G. J.
    Reed, N. S.
    Jayson, G.
    Ledermann, J. A.
    Adams, M.
    Stredder, C.
    Wagner, A.
    Giurescu, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Phase II Study of the Novel Epothilone Sagopilone (ZK-EPO) in Patients with Progressive Metastatic Breast Cancer.
    Campone, M.
    Dittrich, C.
    Cufer, T.
    Dudov, A.
    Phan, Dao P.
    Schmelter, T.
    Giurescu, M.
    Martin, M.
    CANCER RESEARCH, 2009, 69 (24) : 858S - 859S
  • [7] ZK-EPO, a potent third-generation epothilone, is effective in models of breast cancer metastasis
    Hoffmann, Jens
    Fichtner, Iduna
    Klar, Ulrich
    CANCER RESEARCH, 2006, 66 (08)
  • [8] Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial
    D Arnold
    W Voigt
    P Kiewe
    C Behrmann
    S Lindemann
    S Reif
    H Wiesinger
    M Giurescu
    E Thiel
    H-J Schmoll
    British Journal of Cancer, 2009, 101 : 1241 - 1247
  • [9] Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial
    Arnold, D.
    Voigt, W.
    Kiewe, P.
    Behrmann, C.
    Lindemann, S.
    Reif, S.
    Wiesinger, H.
    Giurescu, M.
    Thiel, E.
    Schmoll, H-J
    BRITISH JOURNAL OF CANCER, 2009, 101 (08) : 1241 - 1247
  • [10] Comparative anti proliferative activities and cellular distribution of the third-generation epothilone ZK-EPO and taxanes
    Hoffman, J.
    Winsel, S.
    Hammer, S.
    Mittelstaedt, K.
    Buchmann, B.
    Schwede, W.
    Skuballa, W.
    Siemeister, G.
    Bosslet, K.
    Klar, U.
    EJC SUPPLEMENTS, 2006, 4 (12): : 190 - 190
12345